FDA grants fast track designation to CD33-directed CAR-T for acute myeloid leukemia

FDA grants fast track designation to CD33-directed CAR-T for acute myeloid leukemia - Blog

The FDA has granted accelerated designation to PRGN-3006 for the treatment of adults with relapsed or refractory acute myeloid leukemia. PRGN-3006 (Precigen Inc.) is a CAR T cell therapy that targets the CD33 protein on the surface of cancer cells. This investigational therapy, designed to reduce manufacturing time to 1 day, is based on Precigen’s […]